127 related articles for article (PubMed ID: 38175442)
1. SATB2 expression in hematolymphoid neoplasms.
Tiu GC; Natkunam Y; Fernandez-Pol S
J Hematop; 2023 Jun; 16(2):119-122. PubMed ID: 38175442
[No Abstract] [Full Text] [Related]
2. Practical applications of immunohistochemistry in hematolymphoid neoplasms.
Chu PG; Chang KL; Arber DA; Weiss LM
Ann Diagn Pathol; 1999 Apr; 3(2):104-33. PubMed ID: 10196391
[TBL] [Abstract][Full Text] [Related]
3. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
4. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis of hematolymphoid malignancy by using effusion fluid cytology specimens: a study of 33 cases].
Su XY; Xu X; Tang Y; Li GD
Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):542-6. PubMed ID: 20021966
[TBL] [Abstract][Full Text] [Related]
6. Transcription Factor Expression in Sinonasal Neuroendocrine Neoplasms and Olfactory Neuroblastoma (ONB): Hyams' Grades 1-3 ONBs Expand the Spectrum of SATB2 and GATA3-Positive Neoplasms.
Uccella S; Facco C; Chiaravalli AM; Pettenon F; La Rosa S; Turri-Zanoni M; Castelnuovo P; Cerati M; Sessa F
Endocr Pathol; 2022 Jun; 33(2):264-273. PubMed ID: 35522392
[TBL] [Abstract][Full Text] [Related]
7. SATB2 is expressed in neuroendocrine carcinoma of the uterine cervix.
Inzani F; Angelico G; Santoro A; Travaglino A; Insabato L; Raffone A; Arciuolo D; Scaglione G; D'Alessandris N; Valente M; Carlino A; Rindi G; Zannoni GF
Virchows Arch; 2022 Apr; 480(4):873-877. PubMed ID: 35091815
[TBL] [Abstract][Full Text] [Related]
8. Expression of SATB2 in primary cutaneous sarcomatoid neoplasms: a potential diagnostic pitfall.
Szczepanski JM; Siddiqui J; Patel RM; Harms PW; Hrycaj SM; Chan MP
Pathology; 2023 Apr; 55(3):350-354. PubMed ID: 36732203
[TBL] [Abstract][Full Text] [Related]
9. Hematolymphoid lesions of the sinonasal tract.
Crane GM; Duffield AS
Semin Diagn Pathol; 2016 Mar; 33(2):71-80. PubMed ID: 26472692
[TBL] [Abstract][Full Text] [Related]
10. Significance of SATB2 expression in colon cancer and its differential diagnosis in digestive tract adenocarcinoma and ovarian primary and metastatic carcinoma.
Liu F; Gao Z; Shen D; Zhao H; Wang C; Ye Y; Ma Y; Kong F
Pathol Res Pract; 2019 Jul; 215(7):152430. PubMed ID: 31101576
[TBL] [Abstract][Full Text] [Related]
11. SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors.
Dum D; Kromm D; Lennartz M; De Wispelaere N; Büscheck F; Luebke AM; Burandt E; Menz A; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Lebok P; Sauter G; Simon R; Uhlig R; Wilczak W; Minner S; Krech R; Bernreuther C; Marx A; Steurer S; Jacobsen F; Clauditz T; Krech T
Arch Pathol Lab Med; 2023 Apr; 147(4):451-464. PubMed ID: 35917493
[TBL] [Abstract][Full Text] [Related]
12. Hematolymphoid lesions of the breast.
Hoffmann J; Ohgami RS
Semin Diagn Pathol; 2017 Sep; 34(5):462-469. PubMed ID: 28662998
[TBL] [Abstract][Full Text] [Related]
13. Loss of SATB2 Expression Is a Biomarker of Inflammatory Bowel Disease-associated Colorectal Dysplasia and Adenocarcinoma.
Ma C; Henn P; Miller C; Herbst C; Hartman DJ; Pai RK
Am J Surg Pathol; 2019 Oct; 43(10):1314-1322. PubMed ID: 31318711
[TBL] [Abstract][Full Text] [Related]
14. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
15. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
16. SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material.
Sharma AE; Pytel P; Cipriani NA
Hum Pathol; 2022 Mar; 121():56-64. PubMed ID: 35016891
[TBL] [Abstract][Full Text] [Related]
17. SATB2 in Neoplasms of Lung, Pancreatobiliary, and Gastrointestinal Origins.
De Michele S; Remotti HE; Del Portillo A; Lagana SM; Szabolcs M; Saqi A
Am J Clin Pathol; 2021 Jan; 155(1):124-132. PubMed ID: 32914850
[TBL] [Abstract][Full Text] [Related]
18. SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract.
Ma C; Lowenthal BM; Pai RK
Am J Surg Pathol; 2018 Dec; 42(12):1715-1722. PubMed ID: 30212392
[TBL] [Abstract][Full Text] [Related]
19. Report of proceedings of the national meeting on "Guidelines for Immunophenotyping of Hematolymphoid Neoplasms by Flow Cytometry".
Gujral S; Subramanian PG; Patkar N; Badrinath Y; Kumar A; Tembhare P; Vazifdar A; Khodaiji S; Madkaikar M; Ghosh K; Yargop M; Dasgupta A
Indian J Pathol Microbiol; 2008; 51(2):161-6. PubMed ID: 18603672
[TBL] [Abstract][Full Text] [Related]
20. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
Ma C; Olevian D; Miller C; Herbst C; Jayachandran P; Kozak MM; Chang DT; Pai RK
Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
